Bayer "virtual walk" benefits hemophilia group

Share this article:
Bayer "virtual walk" benefits hemophilia group
Bayer "virtual walk" benefits hemophilia group
Bayer HealthCare Pharmaceuticals is holding a “virtual walk” for the National Hemophilia Foundation (NHF) and its local chapters. The company will sponsor walkers to the tune of up to $60,000.

A Bayer spokesperson said the campaign complements NHF's real walks, and has garnered over 850 signatures in the ten days since its launch, timed to coincide with World Hemophilia Day on April 17 (the company's Bay Area-based US unit took part in an April 16 5K walk in Berkeley to mark the occasion).

Participants in the virtual walk can create a virtual character at walkforhemophilia.com, choose a message and select a local NHF chapter to walk for. The to pthree chapters with the most virtual walkers by November 6 will receive $15,000, $10,000 and $5,000 in sponsorship funds, respectively, while the national office will get up to $30,000. Signatories are prompted to share the event with friends and family via Facebook, Twitter or email.

Paul Bedard, VP/General Manager for hematology at Bayer, said in a statement: “The Virtual Walk for Hemophilia is the latest in a series of innovative programs and services, such as FactorTrack, a mobile application to help track and record infusions for people with bleeding disorders, including those with hemophilia A.”

The company's Consumer Care unit has previously sponsored virtual marches for breast cancer research in support of its One a Day women's multivitamin franchise.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...